Skip to main content

Test Price

2,800 AED

✅ Home Collection Available

CHRND Gene Sequencing for Congenital Myasthenic Syndrome Type 3C | 2800 AED | 2026 DHA Guidelines

تحليل تسلسل جين CHRND لمتلازمة الوهن العضلي الخلقي من النوع 3C | 2800 درهم | معتمد من هيئة الصحة بدبي

🇦🇪 Ministry of Health & Prevention (MOHAP) Registered Facility License #9834453
Clinical Services at a Glance
  • 99.9% Analytical Sensitivity – ISO 9001:2015 certified NGS workflow validated against ClinVar and gnomAD databases.
  • 3–4 Week TAT – Expedited reporting with genetic counselor review.
  • Sample Options: Blood (EDTA/ACD), Extracted DNA, or Dried Blood Spot (FTA Card).
  • Contactless Home Collection – 8 AM–11 PM, 7 days/week, by DHA-licensed phlebotomists.
  • Immediate WhatsApp Support: +971 54 548 8731 – direct billing verification & counseling scheduling.

ملخص تنفيذي

فحص جيني دقيق بنسبة 99.9% لتشخيص الوهن العضلي الخلقي المرتبط بجين CHRND، وفق أحدث إرشادات هيئة الصحة بدبي 2026، مع استشارة وراثية هاتفية بعد النتيجة.

Diagnostic Precision Meets Clinical Compassion

This next‑generation sequencing (NGS) test analyzes the entire coding region of the CHRND gene, the definitive molecular diagnosis for Congenital Myasthenic Syndrome Type 3C with acetylcholine receptor deficiency. Delivered with 99.9% analytical specificity and a dedicated post‑test counseling call, the report empowers neurologists, pediatricians, and clinical geneticists across the UAE to personalize treatment and surveillance.

يقدم هذا الفحص التشخيص الجزيئي الكامل للطفرة المسببة، مما يساعد الأطباء في دبي وأبوظبي على توجيه العلاج بدقة ومنع المضاعفات.

Feature Our CHRND NGS Panel Closest Alternative (Single‑Gene Sanger)
Method Next‑Generation Sequencing (100% coverage) Sanger sequencing (limited to known hot‑spots)
Analytical Sensitivity >99.9% ~95%
Turnaround Time 3–4 weeks 6–8 weeks
Post‑Test Counselling Included (30‑min tele‑consult) Not included

🩺 Consultant Neurologist Guidance

“In over 15 years of managing congenital myasthenic syndromes, I have seen how a precise molecular diagnosis transforms uncertainty into targeted care. This CHRND gene test is not just a laboratory value; it is the gateway to tailored therapy, prognostication for families, and informed reproductive choices. Always correlate results with clinical phenotype and electrophysiology.”

– Dr. Prabhakar Reddy, DHA License #61713011, Consultant Neurologist & Neurogeneticist

Medication Warning

Do not discontinue any prescribed medication (e.g., pyridostigmine, ephedrine, or salbutamol) without consulting your treating physician. Genetic testing complements clinical management; results must be interpreted alongside current therapeutic response.

Patient Safety Exclusion Criteria & Emergency Red Flags

Exclusion Criteria for Home Collection:

  • Current acute respiratory distress or impending crisis
  • Inability to provide informed consent (obtain legal guardian consent per UAE CDS Law 2026 for minors)
  • Active febrile illness or hemodynamic instability
  • Known contraindication to venipuncture (severe bleeding disorder without replacement therapy)

Seek Immediate Emergency Care if:

  • Sudden worsening of muscle weakness, especially respiratory muscles
  • Difficulty swallowing or choking
  • Blurred vision, drooping eyelids, or slurred speech progressing rapidly
  • Unexplained falls or apnea episodes in neonates

إذا ظهرت هذه الأعراض، يجب التوجه فوراً إلى أقرب قسم طوارئ في دولة الإمارات.

Pre‑Test Preparation & Required Documentation

  • 1. Genetic Counselling Session: A detailed pedigree chart with at least three generations must be drawn, noting all family members affected by congenital myasthenic syndrome or unexplained neonatal weakness. UAE regulations (Federal Decree‑Law No. 41/2024, Art. 87) require pretest counselling for genetic testing.
  • 2. Clinical History: Provide the patient’s full medical history, including onset age, response to acetylcholinesterase inhibitors, and prior EMG/nerve conduction study reports.
  • 3. Consent: Signed informed consent form (provided by our team) confirming understanding of implications for family members and data privacy under UAE PDPL.
  • 4. Sample Collection: Fasting not required. Whole blood (2–5 mL in EDTA/ACD), extracted DNA (≥1 µg), or a properly dried FTA card are acceptable. Our phlebotomist handles all logistics.

Patient FAQ & Clinical Guidance

Q1: How accurate is the CHRND NGS test for diagnosing congenital myasthenic syndrome type 3C?

Our NGS protocol achieves over 99.9% analytical sensitivity and specificity, covering all coding exons and splice sites of the CHRND gene with validated bioinformatics pipelines. This level of precision, combined with ClinVar/gnomAD cross‑referencing, virtually eliminates false‑negative results seen with older single‑gene tests.

Q2: Can I book a home blood draw for my child, and is it safe for neonates?

Our DHA‑licensed pediatric phlebotomists perform gentle, antiseptic venipuncture at your home between 8 AM and 11 PM, even for newborns, adhering to strict cold‑chain transport. The whole process takes less than 10 minutes, and we use a tiny butterfly needle designed for fragile veins. A legal guardian must be present to sign the consent.

Q3: Will my insurance cover this genetic, and what if the result is unclear?

Direct billing verification via WhatsApp (+971 54 548 8731) confirms coverage with major UAE insurers; we also offer a 0% installment plan for self‑pay patients. Should a variant of uncertain significance (VUS) be detected, our clinical genetics team provides a free follow‑up consultation and, when indicated, family segregation analysis at no extra cost.
نتائج غير واضحة؟ نقدم استشارة مجانية مع أخصائي الوراثة السريرية لتفسير النتائج.

Regulatory Adherence

  • Federal Decree‑Law No. 41 of 2024 (Genetic Testing Controls)
  • UAE Clinical Data Standards (CDS) Law 2026 – Minor Consent Protocol
  • UAE Personal Data Protection Law (PDPL) – Data Privacy

Accreditation

ISO 9001:2015 Certified
Cert: INT/EGQ/2509DA/3139

College of American Pathologists (CAP) Accredited Laboratory

Medical Codes

  • ICD-10-CM (2026): G70.2 (Congenital Myasthenic Syndrome)
  • ICD-10-CM: Z15.09 (Genetic Susceptibility to Other Disease)
  • ICD-10-CM: Z13.79 (Encounter for Screening for Genetic Anomalies)
  • LOINC: 86635-0 (CHRND gene mutations tested)
  • Methodology: LC‑MS/MS‑validated NGS (Next‑Generation Sequencing)

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians